Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01372384 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 |
| clinicaltrials |
| NCT01204697 | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | completed | Phase 2 | 74 | Hoffmann-La RocheINDUSTRY | 1 | Nov 16, 2015 | clinicaltrials |
| NCT01077713 | A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 86 | Hoffmann-La RocheINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT01057212 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT01204307 | Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation | completed | Phase 2 | 101 | Chang Gung Memorial HospitalOTHER | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | completed | Phase 2 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01578668 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | completed | Phase 2 | 69 | Guangzhou Medical UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00988936 | Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug(K5-101) | completed | Phase 2 | 35 | Siemens Molecular ImagingINDUSTRY | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features | terminated | Phase 2 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00339586 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | unknown | Phase 2 | 40 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 21, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Feb 2, 2016source: clinicaltrials